NTLA

+ Watchlist + Portfolio

Intellia Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $12.12
52-Week Range: $7.95 – $28.25
Market Cap: $1.72B
P/E (TTM): —
EPS (TTM): -3.35
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.36
PEG Ratio: —
Return on Equity: -55.44%
Return on Assets: -30.14%
Gross Margin: 0.00%
Operating Margin: -1472.26%
Profit Margin: 0.00%
Current Ratio: 6.65
Debt/Equity: 0.10
Total Debt: $73.41M
Free Cash Flow: $-249.83M
Revenue Growth: -46.20%
Earnings Growth: —
Enterprise Value: $1.35B

NTLA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$52.12M	$36.27M	$57.88M	$67.67M
Research & Development	$419.98M	$435.07M	$466.31M	$388.86M
Selling, General & Admin	$90.31M	$116.50M	$125.83M	$119.80M
Operating Expenses	$510.29M	$551.57M	$592.14M	$508.66M
Operating Income	-$458.16M	-$515.29M	-$534.26M	-$440.99M
EBITDA	-$450.59M	-$506.31M	-$523.98M	-$425.07M
Pretax Income	-$474.19M	-$481.19M	-$519.02M	-$412.69M
Net Income	-$474.19M	-$481.19M	-$519.02M	-$412.69M
Diluted EPS	-6.16	-5.42	-5.25	-3.81
Diluted Shares	76.97M	88.77M	98.85M	108.38M

NTLA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$523.51M	$226.75M	$189.18M	$155.46M
Receivables	$3.77M	$36.46M	$8.52M	$9.47M
Current Assets	$1.22B	$998.33M	$639.86M	$527.71M
Total Assets	$1.52B	$1.30B	$1.19B	$842.13M
Current Liabilities	$126.55M	$115.21M	$110.85M	$103.88M
Total Debt	$130.70M	$115.35M	$210.20M	$93.33M
Total Liabilities	$284.53M	$250.81M	$319.06M	$170.73M
Retained Earnings	-$1.18B	-$1.66B	-$2.18B	-$2.59B
Shareholders' Equity	$1.24B	$1.05B	$871.96M	$671.39M
Working Capital	$1.09B	$883.12M	$529.01M	$423.83M

NTLA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$333.29M	-$394.09M	-$348.88M	-$394.74M
Capital Expenditure	-$58.39M	-$13.98M	-$5.78M	-$1.13M
Free Cash Flow	-$391.68M	-$408.07M	-$354.66M	-$395.87M
Depreciation & Amortisation	$7.57M	$8.98M	$10.29M	$15.92M
Stock-Based Compensation	$91.40M	$134.05M	$154.27M	$80.22M
Investing Cash Flow	$160.31M	-$31.35M	$125.57M	$228.03M
Financing Cash Flow	$582.96M	$130.32M	$185.75M	$131.49M
Net Change in Cash	$409.98M	-$295.11M	-$37.57M	-$35.22M

NTLA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$16.63M	$14.24M	$13.78M	$23.02M	$15.05M	$7.66M
Research & Development	$108.43M	$97.03M	$94.75M	$88.65M	$80.74M	$82.59M
Selling, General & Admin	$29.01M	$27.21M	$30.51M	$33.08M	$34.84M	$37.82M
Operating Expenses	$137.43M	$124.24M	$125.26M	$121.73M	$115.58M	$120.42M
Operating Income	-$120.81M	-$110.00M	-$111.48M	-$98.71M	-$100.53M	-$112.76M
EBITDA	-$118.31M	-$107.52M	-$106.54M	-$92.69M	-$98.33M	-$110.68M
Pretax Income	-$114.33M	-$101.25M	-$101.32M	-$95.79M	-$96.23M	-$106.63M
Net Income	-$114.33M	-$101.25M	-$101.32M	-$95.79M	-$96.23M	-$106.63M
Diluted EPS	-1.10	-0.98	-0.92	-0.83	-0.81	-0.80
Diluted Shares	103.50M	103.73M	110.19M	115.92M	118.49M	133.48M

NTLA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$126.88M	$156.17M	$193.39M	$155.46M	$134.70M	$106.13M
Receivables	$10.50M	$11.35M	$11.05M	$9.47M	$9.13M	$7.32M
Current Assets	$551.39M	$495.94M	$581.94M	$527.71M	$466.45M	$527.83M
Total Assets	$986.16M	$898.89M	$925.27M	$842.13M	$758.78M	$857.16M
Current Liabilities	$112.59M	$95.50M	$93.73M	$103.88M	$76.44M	$79.39M
Total Debt	$119.25M	$102.59M	$97.97M	$93.33M	$80.49M	$73.41M
Total Liabilities	$206.24M	$183.64M	$176.85M	$170.73M	$137.84M	$129.46M
Retained Earnings	-$2.29B	-$2.39B	-$2.49B	-$2.59B	-$2.69B	-$2.79B
Shareholders' Equity	$779.92M	$715.25M	$748.42M	$671.39M	$620.94M	$727.71M
Working Capital	$438.80M	$400.45M	$488.21M	$423.83M	$390.00M	$448.44M

NTLA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$148.93M	-$99.62M	-$76.90M	-$69.28M	-$117.35M	-$83.11M
Capital Expenditure	-$735.00K	-$239.00K	-$29.00K	-$126.00K	-$79.00K	-$1.81M
Free Cash Flow	-$149.66M	-$99.86M	-$76.93M	-$69.41M	-$117.42M	-$84.92M
Depreciation & Amortisation	$2.50M	$2.47M	$4.94M	$6.01M	$2.20M	$2.08M
Stock-Based Compensation	$21.84M	$22.04M	$19.60M	$16.74M	$13.48M	$18.07M
Investing Cash Flow	$94.33M	$106.91M	-$741.00K	$27.53M	$66.31M	-$141.57M
Financing Cash Flow	$0.00	$14.65M	$114.86M	$1.98M	$33.57M	$196.12M
Net Change in Cash	-$54.60M	$21.94M	$37.22M	-$39.77M	-$17.47M	-$28.57M

Market Snapshot

About

Intellia Therapeutics is a leading genome editing company developing CRISPR/Cas9-based therapies to treat genetic diseases. The company is advancing both in vivo (directly in the body) and ex vivo (cell therapy) programs targeting conditions including transthyretin amyloidosis, hereditary angioedema, and various cancers using its proprietary CRISPR platform.